Closely-held Q32 Bio appointed Adam Cutler as chief financial officer, with responsibility for all aspects of its financial strategy and operations.
Mr. Cutler has more than 20 years of experience in corporate finance, business development, investment banking, equity research, investor relations and management consulting. Prior to joining Q32 Bio, he served as CFO of Molecular Templates. Previously, he was SVP of corporate affairs at Arbutus Biopharma, where his responsibilities included investor relations, business development and corporate finance.
In a statement, Mike Broxson, CEO of Q32 Bio, said Mr. Cutler will be “instrumental as we continue to advance our pipeline of biologic therapeutics that will re-balance immunity in severe autoimmune and inflammatory diseases.”
Mr. Cutler said Q32 Bio has made rapid progress advancing its pipeline of therapies designed to target powerful regulators of the adaptive and innate immune systems as “we strive to generate long term value and ultimately bring much needed therapies to patients in areas of high unmet need.”
